FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Claude Stoll(Génétique Médicale & Génomique Fonctionelle), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Dominik Paul Modest(Berliner Hochschule für Technik), Elke Jäger(Krankenhaus Nordwest), Andreas Jung(Ludwig-Maximilians-Universität München), Tobias Heintges(Lukaskrankenhaus), Jens Neumann(German Cancer Research Center), Clemens Gießen, Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Werner Scheithauer(Comprehensive Cancer Center Vienna), Thomas Decker
Cited by 110
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k